Form 4: Neumora Therapeutics Head of R&D, Robert A. Lenz, Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of NMRA common stock on October 9 and 10, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of the company's common stock on October 9 and 10, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
- On October 9, 2024, 5,563 shares were sold at a weighted average price of $15.0112 per share.
- On October 10, 2024, 8,260 shares were sold at a weighted average price of $15.0851 per share.
- Following these transactions, Lenz directly owns 314,706 shares of Neumora Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports stock sales under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sales are unusually large or frequent.
Comparison to Industry Standards
- Insider sales are a common occurrence in publicly traded companies, particularly among executives holding significant equity.
- The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
- The size of these sales is relatively small compared to the overall market capitalization of Neumora Therapeutics and the holdings of Robert A. Lenz.
- Comparable companies in the biotechnology sector, such as Biogen or Amgen, also see regular Form 4 filings related to insider transactions.
Stakeholder Impact
- The stock sales could have a minor negative impact on shareholder sentiment, but the effect is likely to be minimal given the pre-planned nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| June 12, 2024 | Date of adoption of the Rule 10b5-1 trading plan |
| October 09, 2024 | Date of first reported transaction (sale of 5,563 shares) |
| October 10, 2024 | Date of second reported transaction (sale of 8,260 shares) |
| October 11, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.